<DOC>
	<DOCNO>NCT00990912</DOCNO>
	<brief_summary>The purpose study determine long term safety patient refractory solid tumor experience clinical benefit least 6 cycle treatment BMS Protocol CA124-001 CA124-002 .</brief_summary>
	<brief_title>A Study Document Long-Term Safety Continued Benefit Irinotecan Carboplatin Irinotecan Subjects With Refractory Solid Tumors ( Rollover Study -001 , -002 )</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Completion least 6 cycle therapy BMS clinical protocol CA124001 CA124002 continue derive clinical benefit experience intolerable toxicity therapy Karnofsky score least 50 subject &gt; 10 year age ; Lansky play scale least 50 child 10 year age young Recovery baseline Grade 1 toxicity ( except alopecia asthenia ) result previous therapy Males female , age 1 21 year age time consent CA124001 CA124002 A serious uncontrolled medical disorder opinion Investigator would impair ability subject receive protocol therapy Requirement receive concurrent chemotherapy , immunotherapy , radiotherapy , investigational drug study Inadequate bone marrow renal function Concurrent receipt Dilantin® ( phenytoin ) , phenobarbital , primidone , Tegretol® ( carbamazepine ) , Depacon® , Depakene® , Depakote® , Deproic® ( valproic acid )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>